Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Who Should NOT Consider Peptides Based on current evidence, I would advise against peptide use in the following individuals: Anyone with a current or recent cancer diagnosis Anyone with a strong family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate, colorectal) Anyone with genetic mutations predisposing to cancer (BRCA1/2, Lynch syndrome, etc.) Anyone with active autoimmune disease or severe inflammatory conditions Pregnant or breastfeeding women Anyone who has not established foundational health practices Competitive athletes (most peptides are banned substances) Anyone seeking a "quick fix" rather than commitment to comprehensive health optimization If Considering Peptides: A Cautious Approach For patients who have established solid foundations, have no contraindications, understand the limitations of current evidence, and wish to explore peptides as a potential adjunct, here is the approach I might considerwith significant caveats: Lower-Risk Starting Point Topical GHK-Cu: This has the most established safety profile and documented benefits for skin health
IV therapy with Glutathione is also available for additional benefits
Its currently the only Health Canada-approved dual receptor agonist for treating obesity or overweight
Each mouth-dissolving tablet delivers 500mg of L-glutathione with improved bioavailability, no water needed
doi: 10.1038/s41392-024-01931-z, Summary Keywords central nervous system, feeding behavior, GLP-1 receptor agonists, gutbrain axis, obesity Citation OConnor RM (2026) Revisiting food addiction in the era of GLP-1based obesity pharmacotherapy via neural reward pathways linking feeding and substance use
The developmental dismantling of pluripotency is reversed by ectopic Oct4 expression
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
